There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for patients with stage 3 or 4 kidney cancer, who face high recurrence risk.
In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.
A neoantigen-targeting personalized cancer vaccine may be effective as adjuvant therapy in patients with high-risk clear cell renal cell carcinoma, phase 1 data suggest.
A personalized vaccine against advanced kidney cancer has shown encouraging results in a clinical trial, with all nine ...
HealthDay on MSN3d
Immunogenic Cancer Vaccine Targets Key Mutations in Kidney CancerPersonalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma.
A potential new cancer vaccine could be on the horizon as a study has yielded “exciting” results. Scientists have revealed ...
A groundbreaking study has delivered "exciting" findings, indicating that a new cancer vaccine could be on the verge of ...
Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma. (HealthDay News) — Neoantigen-targeting personalized ...
The new vaccine is "personalized," meaning it is designed to train the patient's immune system to recognize and eliminate any remaining cells of that person's cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback